Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Xpert CT/NG Gets CLIA 'Moderate Complexity' Rating

NEW YORK (GenomeWeb News) – Cepheid today said that the US Food and Drug Administration has categorized the firm's Xpert CT/NG test as moderate complexity under the Clinical Laboratory Improvement Amendments.

Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae. The test runs on Cepheid's GeneXpert molecular testing system, and is the first molecular CT/NG test to be categorized as moderately complex and the twelfth Cepheid test to be categorized as such, the Sunnyvale, Calif.-based firm said.

"Now accessible to more than 20,000 moderately complex US labs and 7,000 high-complexity US labs, Xpert CT/NG becomes an important new weapon in reducing STD rates as clinicians can test, consult with, and treat their patients on a more timely basis," Cepheid CEO John Bishop said in a statement.

Cepheid said it will begin shipping the test this month.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more